Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alintegimod + Ipilimumab Followed by Nivolumab in Advanced Solid Tumors
NCT06362369Phase 2Recruiting
- Sponsor
- 7 Hills Pharma
- Start
- Aug 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alintegimod in solid tumor, melanoma, pleural mesothelioma, renal cell carcinoma (RCC), colorectal cancer (CRC), sponsored by 7 Hills Pharma. Started Aug 2024; status: recruiting.
02
Drugs
alintegimod
03
Conditions
solid tumormelanomapleural mesotheliomarenal cell carcinoma (RCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06362369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06362369.